Adlai Nortye Ltd
ANL
Company Profile
Business description
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Contact
685 US Highway 1
New Jersey Biotechnology Development Center, 2nd floor
North BrunswickNJ08902
USAT: +1 848 230-7430
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
123
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,256.09 | 347.35 | 4.39% |
| DAX 40 | 23,989.33 | 1,067.74 | 4.66% |
| Dow JONES (US) | 47,625.40 | 1,040.94 | 2.23% |
| FTSE 100 | 10,606.84 | 258.05 | 2.49% |
| HKSE | 25,893.02 | 776.49 | 3.09% |
| NASDAQ | 22,538.91 | 521.06 | 2.37% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,748.10 | 131.25 | 1.98% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |